{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:04:45Z","timestamp":1792267485993,"version":"4.4.0"},"reference-count":15,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2020,4,13]],"date-time":"2020-04-13T00:00:00Z","timestamp":1586736000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2020,4,13]],"date-time":"2020-04-13T00:00:00Z","timestamp":1586736000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Laboratory Analysis"],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study was to investigate the changes in circulating microRNA (miR)\u2010125a and miR\u2010125b during infliximab (IFX) treatment, and their value in predicting clinical response to IFX in rheumatoid arthritis (RA) patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The plasma samples were obtained from 96 active RA patients who underwent 24\u2010week IFX treatment and from 96 healthy controls to detect miR\u2010125a and miR\u2010125b expressions by RT\u2010qPCR. Clinical response was assessed according to EULAR criteria based on disease activity alleviation at week 4, week 12, and week 24.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>MiR\u2010125a and miR\u2010125b expressions were both elevated in RA patients compared with healthy controls, and they could differentiate RA patients from healthy controls by receiver operating characteristic curve analysis. Baseline miR\u2010125a positively correlated with C\u2010reactive protein (CRP) level; meanwhile, baseline miR\u2010125b positively correlated with tender joint count (TJC), swollen joint count (SJC), erythrocyte sedimentation rate (ESR), CRP, and DAS28\u2010ESR score in RA patients. With the 24\u2010week IFX treatment, clinical response rate was gradually increased, while miR\u2010125a and miR\u2010125b expressions were gradually decreased in RA patients. At week 24, 69 (71.9%) patients responded to IFX treatment, while 27 (28.1%) patients did not respond to IFX treatment. Importantly, baseline miR\u2010125a and miR\u2010125b expressions were higher in responders than that in non\u2010responders, further multivariate logistic regression analysis disclosed that miR\u2010125b but not miR\u2010125a could independently predict better clinical response to IFX in RA patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Circulating miR\u2010125a and miR\u2010125b displays the potency for guiding personalized treatment strategy and improving clinical outcomes in RA patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/jcla.23329","type":"journal-article","created":{"date-parts":[[2020,4,13]],"date-time":"2020-04-13T04:40:40Z","timestamp":1586752840000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["The potential of circulating microRNA\u2010125a and microRNA\u2010125b as markers for inflammation and clinical response to infliximab in rheumatoid arthritis patients"],"prefix":"10.1002","volume":"34","author":[{"given":"Peng","family":"Cheng","sequence":"first","affiliation":[{"name":"Department of Pharmacy The Central Hospital of Wuhan Tongji Medical College Huazhong University of Science and Technology Wuhan People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7236-5760","authenticated-orcid":false,"given":"Jun","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy The Central Hospital of Wuhan Tongji Medical College Huazhong University of Science and Technology Wuhan People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,4,13]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31472-1"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.7326\/AITC201901010"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pop.2018.02.010"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.30207"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2017.10.002"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.5483\/BMBRep.2016.49.6.056"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150232"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/342524"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2017.07.042"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.27584"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780390105"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2019.102391"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1102001"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.030452"},{"key":"e_1_2_6_16_1","article-title":"MiR\u2010125b but not miR\u2010125a is upregulated and exhibits a trend to correlate with enhanced disease severity, inflammation, and increased mortality in sepsis patients","author":"Zhu X","year":"2019","journal-title":"J Clin Lab Anal"}],"container-title":["Journal of Clinical Laboratory Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjcla.23329","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcla.23329","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jcla.23329","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcla.23329","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T12:49:52Z","timestamp":1776084592000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jcla.23329"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,13]]},"references-count":15,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["10.1002\/jcla.23329"],"URL":"https:\/\/doi.org\/10.1002\/jcla.23329","archive":["Portico"],"relation":{},"ISSN":["0887-8013","1098-2825"],"issn-type":[{"value":"0887-8013","type":"print"},{"value":"1098-2825","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,13]]},"assertion":[{"value":"2020-02-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e23329"}}